← Browse by Condition
Medical Condition
solid tumors refractory to standard therapy
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1, Phase 1, Phase 2
ClinicalMetric tracks all active clinical trials for solid tumors refractory to standard therapy sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Trial Phases
Phase 1 2
Phase 2 1
Top Sponsors
1 trial
1 trial
NCT06883539 Phase 1
Recruiting
A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
Enrollment
24 pts
Location
Taiwan
Sponsor
LaunXP Biomedical Co., Ltd.
NCT06911333 Phase 1, Phase 2
Recruiting
AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors
Enrollment
36 pts
Location
South Korea
Sponsor
Avelos Therapeutics Inc.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology